Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC); Center for Cancer Precision Medicine, CAMS and PUMC, National Institute of Biological Sciences, Collaborative Innovation Center for Cancer Medicine, Beijing, People's Republic of China.
Cancer Rep (Hoboken). 2023 May;6(5):e1800. doi: 10.1002/cnr2.1800. Epub 2023 Mar 15.
The gastrointestinal (GI) tract is the second most frequent extranasal involvement site for ENKTL. This study aimed to explore the clinicopathological features, treatment models, survival outcomes, and prognosis of gastrointestinal ENKTL (GI-ENKTL).
The clinical data of GI-ENKTL patients were extracted from the China Lymphoma Collaborative Group (CLCG) database and were analyzed retrospectively.
A total of 30 patients were enrolled, with a male/female ratio of 4:1 and a median age of 42 years. Twenty-nine patients received chemotherapy, of whom 15 patients received asparaginase-based (ASP-based) regimens. Moreover, seven received surgery and three received radiotherapy. The overall response an d complete remission rates were 50.0% and 30.0% for the whole cohort, 50.0% and 37.5% for patients treated with ASP-based regimens, and 50.0% and 25.0% for those treated with non-ASP-based regimens, respectively. The median follow-up was 12.9 months and the 1-year overall survival rate was 40.0% for the whole cohort. For those patients in an early stage, ASP-based regimens resulted in a superior 1-year progression-free survival rate compared to non-ASP-based regimens (100.0% vs. 36.0%, p = .07). However, ASP-based regimens did not improve survival in patients at an advanced stage.
GI-ENKTL still has a poor prognosis, even in the era of modern asparaginase-based treatment strategies.
胃肠道（GI）是结外 NK/T 细胞淋巴瘤（ENKTL）第二常见的非鼻腔受累部位。本研究旨在探讨胃肠道 ENKTL（GI-ENKTL）的临床病理特征、治疗模式、生存结局和预后。
从中国淋巴瘤协作组（CLCG）数据库中提取 GI-ENKTL 患者的临床资料，进行回顾性分析。
共纳入 30 例患者，男女比例为 4:1，中位年龄为 42 岁。29 例患者接受化疗，其中 15 例接受含门冬酰胺酶（ASP）方案。此外，7 例患者接受手术，3 例患者接受放疗。全组患者的总缓解率和完全缓解率分别为 50.0%和 30.0%，ASP 方案组分别为 50.0%和 37.5%，非 ASP 方案组分别为 50.0%和 25.0%。中位随访时间为 12.9 个月，全组患者的 1 年总生存率为 40.0%。对于早期患者，ASP 方案组的 1 年无进展生存率优于非 ASP 方案组（100.0% vs. 36.0%，p=0.07）。然而，ASP 方案在晚期患者中并未改善生存。
即使在现代含 ASP 治疗策略的时代，GI-ENKTL 预后仍较差。
